Live Breaking News & Updates on Mmunogenicity

Stay informed with the latest breaking news from Mmunogenicity on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mmunogenicity and stay connected to the pulse of your community

Novel Immunogenicity Risk Assessment Platform | ISPRI | Facilitates Biologic Therapeutics Development

PROVIDENCE, R.I., April 1, 2024 /PRNewswire/ -- In the pursuit of developing Novel Biologic entities, scientists harnessing the power of AI and generative ...

Facilitates-biologic-therapeutics-development , Elicio-therapeutics-inc , Novelimmunogenicity-risk-assessment-platform , Elicio-therapeutics-reports , Provides-corporate-updates , Therapeutics-reports , Novel , Mmunogenicity , Isk , Ssessment , Latform

LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V

SCHLIEREN, Switzerland, February 22, 2024--LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants in low- and middle-income countries. In the nine-month-old target population, administration of S

Kenya , United-kingdom , Switzerland , Limmatech-biologics , Alexander-siebert , Patricia-martin , Franz-werner-haas , Network-meeting , Trophic-communications , Wellcome , Chief-operating-officer , Annual-network-meeting

Investigating a role for complement in gene therapy

Immunology expert discusses the complement system, immunogenicity challenges in AAV-mediated gene therapy, and more

Sweden , Swedish , Klaudia-kuranda , Anna-majowicz , Technology-department-at-spark-therapeutics , Technology-department , Editorial-article , Spark-therapeutics , Preclinical-immunology-lead , Svar-life-science , Functional-complement-assays , Complement-system

WHO for introduction of dengue vaccine in India

As dengue cases, particularly in Delhi, show a steep increase, the World Health Organisation has recommended introduction of dengue vaccine in high burden countries including India.

India , Indonesia , Brazil , Delhi , Mexico , World-health-organisation , Drugs-controller-general , Engue-prevention , Engue-vaccine , Mmunogenicity , Engue-vaccination-in-india

Frontiers | Comparison of vaccination schedules for foot-and-mouth disease among cattle and sheep in Mongolia

Vaccines are a critical tool for the control strategy for foot-and-mouth disease (FMD) in Mongolia where sporadic outbreaks regularly occur. A two-dose primary vaccination course is recommended for most commercial vaccines though this can be logistically challenging to deliver among nomadic pastoralist systems which predominate in the country. Although there is evidence that very high potency vaccines can provide prolonged duration of immunity, this has not been demonstrated under field conditions using commercially available vaccines. This study compared neutralising titres to a O/ME-SA/Panasia strain over a six-month period following either a two-dose primary course or a single double-dose vaccination among Mongolian sheep and cattle using a 6.0 PD50 vaccine. Titres were not significantly different between groups except in sheep at six-months post vaccination when the single double-dose group had significantly lower titres. These results indicate the single double-dose regimen may be a cost-effective approach for vaccination campaigns supporting FMD control in Mongolia.

Mongolia , Iraq , Wilsden , Bradford , United-kingdom , Orkhon , Bulgan , Italy , Texas , United-states , Ulaanbaatar , Russia

MyJournals.org - Science - 'Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study' (BMC Nephrology)

MyJournals.org - Science - 'Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study' (BMC Nephrology)

Indonesia , Yogyakarta , Myjournals , Ournals , Atest , Ssues , Rticles , Cience , Mmunogenicity , Nd , Afety

Clinical trial begins for universal flu vaccine candidate

NIH researchers have begun clinical trials on an experimental universal influenza vaccine that may eliminate the need for annual flu vaccines.

Hugh-auchincloss , Elissa-wolfson , Duke-university , Centers-for-disease , National-institute-of-allergy , Science-advisory-board , Infectious-diseases , Disease-control , Influenza-vaccine , Lu-vaccine , Niversal-flu-vaccine , 1ssf-3928-mrna-lnp

Achilles Therapeutics PLC: Achilles Therapeutics' New Immunogenicity Prediction Application of its AI-Powered PELEUS Platform Uniquely Identifies the Most Potent T Cell Antigens

- New AI module delivers a "Target-to-T cell" approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches -LONDON, May 10, 2023 (GLOBE NEWSWIRE) --

United-kingdom , London , City-of , Melissa-gardiner , Sukaina-virji , Mary-jane-elliott , Sergio-quezada , Bioinformatics-data-science-team-at-achilles , Nasdaq , Cancer-research-united-kingdom , National-institute-of-allergy , Achille-material-acquisition-program

Gyros Protein Technologies Introduces Gyrolab Generic Cyno ADA Kit Reagents to Support Pre-Clinical Immunogenicity Assessment

Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in cyno samples Gyros Protein Technologies AB, a leading provider of peptide synthesizers and

Mark-vossenaar , Ben-rutter , Zyme-communications , Biopharmaceutical-development-division , Cyno-anti-drug-antibodies , Kit-reagents , Gyrolab-mixing , General-manager , Gyros-protein-technologies , Gyrolab-generic-cyno , Gyros , Rotein

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2... | February 21, 2023

United-states , Jim-wassil , Jennifer-zibuda , Janet-graesser , Groupa-strep , Drug-administration , Advisory-committee-on-immunization-practices , Nasdaq , Exchange-commission , Sutro-biopharma-inc , Corporate-communications , Initiation-of-pediatric-program-in-infants